A renewed and updated independent in-vitro study performed by one of the most reputable research institutes in the country, specifically targeting the CofixRX Nasal Spray efficacy against the SARS-Cov-2 virus and its most recent and highly infectious variants, Delta and Omicron. The study also certifies the unrelenting undiminishable efficacy and strength of the product 6 and 24 hours after its first application.
A Review of Safety in the COVID-19 Era of PVP-I topically applied to the nasal and oral cavity.
The SARS-CoV-2 – or novel coronavirus – enters in human body through nose and mouth, stays there for a while. Then binds with ACE2 receptor, enters inside cell, multiply there and manifests. It is already established that PVP-I is a strong microbicidal (chemical) agent, having 99.99% virucidal efficacy in its only 0.23% concentration, irrespective of all known viruses, even in SARS-CoV-2 (in vitro)
Povidone-iodine (PVP-I) is a time-tested antiseptic agent with excellent virucidal (99.99%) properties. Repurposing it against coronavirus disease-19 (COVID-19) is a relatively newer concept and has been sparsely tested in vivo. The most common route of entry of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is the nasopharynx. Hence, it was targeted to prevent access and contamination of the nasopharynx by several protective measures, including facemasks. Averting colonization of the virus could be one of the best options to reduce the incidence of infection.
An important independent study from one of the most reputable research institute in the country focused on CofixRX Nasal Spray efficacy against the SARS-Cov-2 in a in-vitro study.
The report from the Institute for Antiviral Research at Utah State University presents the results from testing the virucidal (Virucidal is defined by Merriam Webster’s dictionary as “having the capacity to or tending to destroy or inactivate viruses.”) effect of CofixRx Nasal Spray against SARS-CoV-2 (Covid-19), Influenza B (the flu), HRV-14 (common cold), and RSV.
This study, from Samantha Frank, MD, Division of Otolaryngology−Head and Neck Surgery, Department of Surgery, University of Connecticut School of Medicine, is among countless other studies that is intended to demonstrate the In-Vitro efficacy of a Povidone-Iodine Nasal Antiseptic in the fight against SARS-CoV-2.
There are several questions and concerns related to the current worldwide situation, potential treatments, and protective measures. Being CofixRX Nasal Spray a product that acts as an additional layer of protection against viruses and pathogens, proven to destroy even SARS-Cov-2 in 45 seconds, this document is intended to help answer few important questions about the product and how to use it.